Listeriosis Market

Market Overview:

The 7 major listeriosis markets are expected to exhibit a CAGR of 4.08% during 2024-2034.

The listeriosis market has been comprehensively analyzed in IMARC's new report titled "Listeriosis Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Listeriosis refers to a bacterial infection caused by the pathogen Listeria monocytogenes. This bacterium is commonly found in soil, water, and certain animals, making it a potential contaminant in various types of food. The infection primarily affects individuals with weakened immune systems, pregnant women, newborns, and the elderly. The symptoms of listeriosis can vary and often include fever, muscle aches, nausea, diarrhea, and gastrointestinal distress. In more severe cases, the disorder can lead to complications, such as septicemia, meningitis, and even death. Pregnant women suffering from the ailment can also experience miscarriages, stillbirths, or numerous other adverse outcomes for their unborn babies. The diagnosis of listeriosis is typically based on a combination of clinical findings and laboratory investigations. A healthcare provider might also perform blood or cerebrospinal fluid cultures to isolate the Listeria bacteria and confirm the diagnosis. Early detection of the disease is crucial to initiate timely treatment for patients.

The escalating incidences of bacterial infection caused by the consumption of contaminated food, particularly dairy products, deli meats, and unwashed vegetables, are primarily driving the listeriosis market. In addition to this, the inflating utilization of effective antibiotics, such as ampicillin and gentamicin, along with advanced medical interventions like intravenous fluid administration and supportive care, is also creating a positive outlook for the market. Moreover, the widespread adoption of stringent food safety regulations and practices to curb the spread of the infection among individuals is further bolstering the market growth. Apart from this, the rising usage of surveillance systems and diagnostic technologies for early detection and swift management of listeriosis cases is acting as another significant growth-inducing factor. These measures aid in the prompt identification of outbreaks, enabling timely interventions, and preventing the widespread transmission of the bacteria. Additionally, the emerging popularity of public health campaigns that emphasize the significance of safe food preparation and storage practices is also augmenting the market growth. Furthermore, the increasing application of bacteriophage therapy, which involves using naturally occurring viruses that specifically target and eliminate certain pathogenic bacteria, thereby reducing the development of the disease, is expected to drive the listeriosis market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the listeriosis market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for listeriosis and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the listeriosis market in any manner.

Key Highlights:

• Listeriosis is a relatively rare condition, with 0.1 to 10 cases per 1 million individuals every year varying by country and area.
• According to the Centers for Disease Control and Prevention, an estimated 1,600 persons in the United States acquire a serious infection from Listeria bacteria in food each year, with approximately 260 of them dying.
• Sporadic listeriosis tends to be more common in the spring and summer seasons.
• Every year, 4 in 100,000 pregnant women in the United States become ill with Listeria.
• Infection most usually occurs within the first 30 days of life or in people over the age of 60.

Time Period of the Study

•  Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the listeriosis market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the listeriosis market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current listeriosis marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance

Key Questions Answered in this Report:

Market Insights

• How has the listeriosis market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the listeriosis market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the listeriosis market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of listeriosis across the seven major markets?
• What is the number of prevalent cases (2018-2034) of listeriosis by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of listeriosis by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with listeriosis across the seven major markets?
• What is the size of the listeriosis patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of listeriosis?
• What will be the growth rate of patients across the seven major markets?
   

Listeriosis: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for listeriosis drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the listeriosis market?
• What are the key regulatory events related to the listeriosis market?
• What is the structure of clinical trial landscape by status related to the listeriosis market?
• What is the structure of clinical trial landscape by phase related to the listeriosis market?
• What is the structure of clinical trial landscape by route of administration related to the listeriosis market?